河北医学
河北醫學
하북의학
HEBEI MEDICINE
2014年
1期
40-42
,共3页
缬沙坦%维持性血液透析%微炎症%肺功能%影%响
纈沙坦%維持性血液透析%微炎癥%肺功能%影%響
힐사탄%유지성혈액투석%미염증%폐공능%영%향
Valsartan%Maintenance hemodialysis%Microinflammation%Pulmonary function%Influence
目的:观察维持性血液透析患者应用缬沙坦治疗微炎症及肺功能的影响。方法:选取我院2007年5月至2012年10月收治的90例尿毒症(维持性血液透析超过3个月)患者按照治疗方法不同随机分为治疗组30例与对照组60例,治疗组在对照组常规治疗同时加用缬沙坦胶囊80 mg 口服,1次/d ,连续治疗3个月后比较两组患者微炎症指标及肺功能参数。结果:治疗前两组患者微炎症及肺功能指标均无明显差异(P>0.05),但治疗3个月后,治疗组各项指标均较治疗前降低(P<0.05),较同期对照组有明显差异(P<0.05),具有统计学意义。结论:维持性血液透析患者应用缬沙坦治疗可改善微炎症及肺功能水平,可提高患者生活质量和改善预后。
目的:觀察維持性血液透析患者應用纈沙坦治療微炎癥及肺功能的影響。方法:選取我院2007年5月至2012年10月收治的90例尿毒癥(維持性血液透析超過3箇月)患者按照治療方法不同隨機分為治療組30例與對照組60例,治療組在對照組常規治療同時加用纈沙坦膠囊80 mg 口服,1次/d ,連續治療3箇月後比較兩組患者微炎癥指標及肺功能參數。結果:治療前兩組患者微炎癥及肺功能指標均無明顯差異(P>0.05),但治療3箇月後,治療組各項指標均較治療前降低(P<0.05),較同期對照組有明顯差異(P<0.05),具有統計學意義。結論:維持性血液透析患者應用纈沙坦治療可改善微炎癥及肺功能水平,可提高患者生活質量和改善預後。
목적:관찰유지성혈액투석환자응용힐사탄치료미염증급폐공능적영향。방법:선취아원2007년5월지2012년10월수치적90례뇨독증(유지성혈액투석초과3개월)환자안조치료방법불동수궤분위치료조30례여대조조60례,치료조재대조조상규치료동시가용힐사탄효낭80 mg 구복,1차/d ,련속치료3개월후비교량조환자미염증지표급폐공능삼수。결과:치료전량조환자미염증급폐공능지표균무명현차이(P>0.05),단치료3개월후,치료조각항지표균교치료전강저(P<0.05),교동기대조조유명현차이(P<0.05),구유통계학의의。결론:유지성혈액투석환자응용힐사탄치료가개선미염증급폐공능수평,가제고환자생활질량화개선예후。
Objective:To observe the effect of valsartan on microinflammation and pulmonary function of maintenance hemodialysis patients.Method:90 cases of uremia ( maintenance hemodialysis for more than 3 months) patients in our hospital from May 2007 to Oct.2012 were selected , according to the different treatment methods, they were randomly divided into treatment group with 30 cases and control group with 60 cases, the treatment group were added with valsartan capsules 80mg orally on the base of routine treatment for control group, once a day, continuous treatment after 3 months, microinflammation index and pulmonary function parameters of two groups of patients were compared .Results:Before treatment , microinflammation and lung function indexes of the two groups were not significantly different ( P>0 .05 ) , but 3 months after treatment, the indexes of the treatment group were decreased significantly (P<0.05), There's significant difference (P<0.05) comparing with the control group.Conclusion: Maintenance hemodialysis patients u-sing valsartan can improve the inflammation and pulmonary function, and it can improve the quality of life of patients and improve the prognosis .